• Applied Protocols with GDC-0068 (RG7440) for Akt Pathway Inh

  2026-07-01

  GDC-0068 (RG7440) empowers researchers to dissect the PI3K/Akt/mTOR axis with high selectivity across diverse cancer models. This guide delivers stepwise protocols, troubleshooting, and practical insights—bridging advanced pathway discoveries with robust, reproducible experimental workflows.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Me

  2026-07-01

  Xiao et al. (2024) uncover how tumor-associated macrophages accumulate 25-hydroxycholesterol (25HC), activating the AMPK pathway through a lysosomal mechanism to drive immunosuppressive functions. This mechanistic insight identifies CH25H as an immunometabolic checkpoint and suggests new strategies for modulating tumor immunity.

• Morning Endurance Training Enhances Adaptation in Mice

  2026-06-30

  Hesketh et al. demonstrate that the timing of endurance exercise crucially shapes adaptation in mice, with morning training inducing greater performance improvements and muscle metabolic remodeling than afternoon sessions. These findings underscore the importance of circadian timing in experimental design and highlight the necessity for precise glycogen quantification in metabolic adaptation studies.

• CX-5461: RNA Polymerase I Inhibitor in Cancer Research Workf

  2026-06-30

  CX-5461 is redefining cancer research by enabling targeted inhibition of ribosome biogenesis and precise modulation of tumor cell fate. This guide delivers stepwise workflows, troubleshooting strategies, and experimental insights to maximize the impact of this unique RNA polymerase I inhibitor in solid tumor and combination therapy studies.

• BMX-IN-1: Advancing BMX Kinase Inhibitor Research in Cancer

  2026-06-29

  BMX-IN-1, a highly selective and irreversible BMX kinase inhibitor from APExBIO, is reshaping the landscape of translational research across oncology and infectious disease. This thought-leadership article integrates cutting-edge mechanistic findings—including recent studies on Mycobacterium tuberculosis immune evasion—with practical guidance for researchers leveraging BMX-IN-1 in both cancer and host-pathogen models. The discussion progresses from biological rationale to experimental protocols, competitive context, and strategic outlook, offering actionable insights for scientists seeking to harness BMX kinase inhibition for therapeutic innovation.

• Structure-Based Screening of Natural Inhibitors for SARS-CoV

  2026-06-29

  This article examines a structure-based virtual screening study that identified potent natural product inhibitors targeting the SARS-CoV-2 NSP15 endoribonuclease. The work provides a model for leveraging in silico methods to discover antiviral agents and highlights implications for translational research on viral immune evasion.

• Taltirelin Improves Motor Function in PD Rats Without Dyskin

  2026-06-28

  Zheng et al. (2018) demonstrated that Taltirelin, a long-acting TRH analog, enhances motor performance in hemi-Parkinsonian rats by sustaining dopamine release without triggering dyskinesia. Their findings reveal a mechanistic profile distinct from conventional L-DOPA therapy, supporting further exploration of Taltirelin in Parkinson’s disease research.

• DHHC9-STRN4-YAP Axis: Targeting Palmitoylation in Cancer Met

  2026-06-27

  This article reviews how the identification of DHHC9-mediated STRN4 palmitoylation provides a novel mechanism for promoting YAP-driven cancer metastasis, and demonstrates the therapeutic potential of DHHC9 inhibitors. These findings offer new directions for targeted intervention in metastatic cancers via modulation of post-translational modifications.

• Strategic Smad3 Inhibition: SIS3 for Translational Fibrosis

  2026-06-26

  Explore how SIS3, a potent Smad3 inhibitor, drives innovation in fibrosis, osteoarthritis, and renal disease research by advancing mechanistic insight and translational strategy. This article offers protocol guidance, competitive context, and a visionary outlook for researchers leveraging the TGF-β/Smad3 pathway.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-06-26

  This study reveals that select p38 MAPK inhibitors not only block kinase activity but also promote dephosphorylation of p38α by stabilizing a distinct activation loop conformation. These findings suggest a dual-action paradigm for kinase inhibitor design with potential to enhance specificity and efficacy for inflammation research.

• AZ505 SMYD2 Inhibitor: Applied Workflows in Epigenetic Resea

  2026-06-25

  AZ505 empowers researchers to dissect SMYD2-driven epigenetic regulation across cancer and fibrosis models with high selectivity and nanomolar potency. This article delivers actionable protocols, troubleshooting guidance, and evidence-linked insights for leveraging AZ505 in translational discovery.

• Translating α-Linolenic Acid Research: Mechanisms to Impact

  2026-06-25

  This article offers translational researchers a multidimensional perspective on α-Linolenic Acid (ALA), moving beyond standard product overviews to synthesize mechanistic depth, protocol innovation, and strategic guidance. By integrating recent advances in immunometabolism, cardiovascular research, and lipid signaling, it provides actionable insights and protocol parameters that drive experimental rigor. APExBIO’s α-Linolenic Acid is positioned as a critical tool for exploring these frontiers, with practical recommendations grounded in both primary literature and workflow best practices.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-06-24

  This study demonstrates that pharmacological inhibition of SMYD2, using agents such as AZ505, alleviates renal fibrosis and inflammation in a cisplatin-induced chronic kidney disease (CKD) model. The findings highlight a significant role for SMYD2 in mediating pro-fibrotic and inflammatory pathways, suggesting new avenues for epigenetic regulation research in kidney disease.

• Technical Use of HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-06-23

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the need for consistent, high-yield fluorescent RNA probe synthesis for applications such as in situ hybridization and Northern blotting. It is strictly intended for research workflows requiring randomly Cy3-labeled RNA probes, and should not be used for diagnostic or therapeutic purposes.

• CX-5461: Mechanistic Insights and Practical Guidance for RNA

  2026-06-23

  Explore the mechanistic depth and advanced application of CX-5461, a potent RNA polymerase I inhibitor, in cancer research. This article uniquely dissects recent discoveries and provides practical guidance for maximizing solid tumor growth inhibition.

15291 records 1/1020 page Next 12345 下5页 Last page